Belpointe Asset Management LLC Takes $752,000 Position in ResMed Inc. $RMD

Belpointe Asset Management LLC bought a new position in shares of ResMed Inc. (NYSE:RMD) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,748 shares of the medical equipment provider’s stock, valued at approximately $752,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Sawgrass Asset Management LLC purchased a new position in shares of ResMed during the 3rd quarter worth approximately $269,000. CIBC Asset Management Inc grew its holdings in ResMed by 0.4% during the 3rd quarter. CIBC Asset Management Inc now owns 20,668 shares of the medical equipment provider’s stock valued at $5,657,000 after buying an additional 78 shares during the last quarter. 1834 Investment Advisors Co. purchased a new position in ResMed during the third quarter worth $570,000. Sagespring Wealth Partners LLC raised its holdings in shares of ResMed by 3.5% in the third quarter. Sagespring Wealth Partners LLC now owns 2,026 shares of the medical equipment provider’s stock worth $554,000 after acquiring an additional 69 shares during the last quarter. Finally, Oxbow Advisors LLC lifted its position in shares of ResMed by 0.9% in the third quarter. Oxbow Advisors LLC now owns 27,521 shares of the medical equipment provider’s stock valued at $7,533,000 after acquiring an additional 235 shares in the last quarter. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other ResMed news, Director Witte Jan De sold 2,055 shares of ResMed stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $255.00, for a total transaction of $524,025.00. Following the transaction, the director directly owned 4,261 shares in the company, valued at approximately $1,086,555. The trade was a 32.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $248.83, for a total value of $497,660.00. Following the sale, the director directly owned 66,773 shares of the company’s stock, valued at $16,615,125.59. This trade represents a 2.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 21,594 shares of company stock worth $5,403,495 in the last three months. 0.65% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on RMD shares. Robert W. Baird set a $281.00 target price on shares of ResMed in a research note on Friday. Mizuho lowered their target price on shares of ResMed from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. Wells Fargo & Company boosted their price target on ResMed from $265.00 to $270.00 and gave the company an “equal weight” rating in a report on Friday. Weiss Ratings restated a “hold (c+)” rating on shares of ResMed in a report on Monday, December 29th. Finally, UBS Group reaffirmed a “buy” rating and issued a $345.00 price objective on shares of ResMed in a research report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $297.91.

ResMed Stock Up 0.1%

Shares of NYSE RMD opened at $257.76 on Friday. The stock’s 50-day simple moving average is $251.04 and its 200-day simple moving average is $263.22. ResMed Inc. has a 1 year low of $199.92 and a 1 year high of $293.81. The firm has a market cap of $37.62 billion, a price-to-earnings ratio of 25.50, a PEG ratio of 1.73 and a beta of 0.88. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.13 and a current ratio of 2.89.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. The company had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.40 billion. ResMed had a net margin of 27.53% and a return on equity of 25.68%. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period last year, the business earned $2.43 EPS. As a group, equities analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Thursday, February 12th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, February 12th. ResMed’s payout ratio is presently 24.56%.

ResMed News Roundup

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat consensus — GAAP diluted EPS of $2.68 (non‑GAAP $2.81) vs. Street estimates ~ $2.68, revenue $1.423B (+11% YoY), 320 bps gross‑margin improvement and $340M operating cash flow. These metrics support near‑term earnings credibility and cash generation. Read More.
• Positive Sentiment: Board declared a quarterly cash dividend of $0.60 per share (record Feb 12; payable Mar 19), signaling capital return commitment and supporting income investors. Read More.
• Positive Sentiment: Product/innovation catalysts: FDA cleared an AI‑enabled device (“Smart Comfort”) to personalize CPAP settings — strengthens digital/AI positioning and could boost adherence and recurring device/accessory demand. Read More.
• Positive Sentiment: Wells Fargo nudged its price target to $270 (from $265) with an “equal weight” rating — a modest analyst lift that implies limited near‑term upside from that shop. Read More.
• Neutral Sentiment: Analyst landscape remains mixed but generally favorable — several firms maintain outperform/buy views and available median targets sit materially above current price, leaving room for differing investor expectations. Read More.
• Neutral Sentiment: Company hosted the Q2 webcast and transcripts are posted — useful for hearing management’s guide/comments on demand, supply and margin outlook. Read More.
• Negative Sentiment: Expenses rose: SG&A and R&D both increased (~12% YoY) and the company recorded $6M in restructuring charges; higher operating costs could pressure margins if growth slows. Read More.
• Negative Sentiment: Notable insider selling activity was reported in recent months (multiple sales by senior executives), which some investors view as a modest governance/conviction caution. Read More.

ResMed Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.